Identifying new genes linked to hereditary uveal melanoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to identify new candidate genes that may contribute to hereditary predisposition to uveal melanoma, a type of eye cancer. Currently, only 20% of familial cases are explained by known genetic factors, suggesting that other hereditary predispositions exist. By conducting constitutional exome analysis on patients with a history of uveal melanoma, the researchers hope to uncover additional genetic markers that could inform better surveillance and management for affected families.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient with a personal history of uveal melanoma (newly diagnosed, under treatment or in follow-up)
* Enrolled in or benefiting from a social security scheme

Exclusion Criteria:

* Causal pathogenic variation identified in BAP1 or MBD4
* Patient does not consent to constitutional genetic analysis for diagnostic purposes
* Patient not consenting to a constitutional genetic analysis for research purposes
* Pregnant and breast-feeding women
* Patients under guardianship or trusteeship

Where it's running

• Centre Jean PERRIN
  Clermont-Ferrand, Puy-de-Dôme, France Recruiting

Study contacts

• Principal investigator: Mathis LEPAGE, Dr — Centre Jean Perrin
• Study coordinator: Angeline GINZAC COUVÉ
• Email: angeline.ginzac@clermont.unicancer.fr
• Phone: 0473278005

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-precision radiosurgery followed by minimally invasive eye-sparing surgery for prominent uveal melanoma

  This study tests a modern, precise radiosurgery approach followed by a minimally invasive surgery to see if it can control the tumor while preserving vision in patients with high-prominence uveal melanoma.

  Recruiting at 3 sites University Hospital, Essen · Essen, Germany / NRW and 2 other locations · NCT07913412

• Adjuvant darovasertib and crizotinib in high-risk non-metastatic uveal melanoma

  Researchers are testing whether adding darovasertib and crizotinib after local eye tumor treatment can help prevent recurrence in people with high-risk, non-metastatic uveal melanoma.

  Recruiting at 4 sites Phase 3 IDEAYA Biosciences · Scottsdale, Arizona and 12 other locations · NCT07804186

• Neoadjuvant immunotherapy for high-risk eye melanoma

  This trial tests whether giving nivolumab and ipilimumab before surgery is safe and feasible for adults with high-risk uveal melanoma.

  Recruiting Phase 1 Herlev Hospital · Herlev, Herlev · NCT07501117

• Immune response after delivering melphalan directly to the liver for uveal (eye) melanoma that has spread to the liver.

  This test will see how the liver's immune system responds when people with uveal melanoma that has spread to the liver receive melphalan delivered directly to the liver through percutaneous hepatic perfusion.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT07364474

• Adding IL-2 to tebentafusp to overcome resistance in uveal melanoma

  This trial tests whether giving interleukin‑2 (IL‑2) together with tebentafusp can help people with HLA‑A*02:01 metastatic uveal melanoma who progressed on tebentafusp.

  Recruiting Phase 1/2 St Vincent's Hospital, Sydney · Sydney, New South Wales and 1 other locations · NCT07063875

• Darovasertib before local treatment for primary uveal melanoma

  This trial tests whether giving darovasertib before surgery or radiation helps people with primary non-metastatic uveal melanoma.

  Recruiting at 25 sites Phase 3 IDEAYA Biosciences · Scottsdale, Arizona and 93 other locations · NCT07015190

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.